Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright dropped their target price on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating for the company in a […]
More Stories
US Adds 562,000 Millionaires as Global Wealth Climbs, Capgemini Finds
By Chase Smith The United States produced more new millionaires than any other country in 2024, helping lift the global...
Trump Signs Orders on Deregulating Flying Cars, Supersonic Flight
By Jacob Burg President Donald Trump signed executive orders on June 6 to deregulate and open research and development into...
Heck Capital Advisors LLC Purchases New Holdings in NVIDIA Co. (NASDAQ:NVDA)
Heck Capital Advisors LLC purchased a new stake in NVIDIA Co. (NASDAQ:NVDA – Free Report) in the fourth quarter, according...
NVIDIA Co. (NASDAQ:NVDA) Stake Increased by Azzad Asset Management Inc. ADV
Azzad Asset Management Inc. ADV grew its stake in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 0.5% during...
Fidelity D & D Bancorp Inc. Cuts Holdings in NVIDIA Co. (NASDAQ:NVDA)
Fidelity D & D Bancorp Inc. reduced its holdings in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 5.5%...
Armis Advisers LLC Invests $4.22 Million in NVIDIA Co. (NASDAQ:NVDA)
Armis Advisers LLC bought a new position in NVIDIA Co. (NASDAQ:NVDA – Free Report) during the 4th quarter, according to...